The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)-Reference-Cited by-同舟云学术

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Published:2010-06 Issue:24 Volume:55 Page:2721-2726
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Villines Todd C.,Stanek Eric J.,Devine Patrick J.,Turco Mark,Miller Michael,Weissman Neil J.,Griffen Len,Taylor Allen J.

Funder

Henry M. Jackson Foundation

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference14 articles.

1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins;Baigent;Lancet,2005

2. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS);Devine;Cardiovasc Drugs Ther,2007

3. Extended-release niacin or ezetimibe and carotid intima-media thickness;Taylor;N Engl J Med,2009

4. A multiple testing procedure for clinical trials;O’Brien;Biometrics,1979

5. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study;Holme;Eur J Cardiovasc Prev Rehabil,2009

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in glucose metabolism, C-reactive protein, and liver enzymes following intake of NAD + precursor supplementation: a systematic review and meta‐regression analysis;Nutrition & Metabolism;2024-06-24

2. The Changing Face of Atherosclerosis;The Indonesian Biomedical Journal;2023-06-26

3. Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis;International Journal of Molecular Sciences;2022-12-19

4. Investigation of the clinical effects of acipimox in patients with vulnerable carotid atherosclerosis;Vascular;2022-07-20

5. Consenso latinoamericano para el manejo del riesgo residual cardiometabólico. Consenso realizado por la Academia Latinoamericana de Lipidología y Riesgo Cardiometabólico (ALALIP), con el aval de la Sociedad Interamericana de Cardiología (SIAC), la Sociedad Interamericana de Aterosclerosis (IAS) y el Colegio Panamericano de Endotelio (PACE);Archivos de Cardiología de México;2021-11-23